Drug intelligence / Profile preview

IL-BTM

Development stage: Preclinical
Lead developer: PARAS Biopharma
Modality: Recombinant Proteins and Enzymes

Overview

IL-BTM (also known as PB(CT)-4010) is a recombinant protein biobetter developed by Paras Biopharmaceuticals. It is designed to target the Interleukin-1 receptor (IL-1R), functioning as an antagonist to block IL-1 signaling pathways. The drug is currently in preclinical development for the treatment of Multiple Myeloma within the oncology therapeutic area. As a biobetter, IL-BTM is engineered to provide improved therapeutic properties, such as enhanced efficacy or superior pharmacological profile, compared to existing IL-1 receptor antagonists.

Brand names: IL-BTM

Targets

IL-1R (Interleukin-1 receptor type 1 (IL-1R1))

Beyond the preview

Go deeper on IL-BTM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-BTM.

Explore the full profile